Henry sells the market’s best-known flat number — the structure we favor on principle because flat rates make teaser math impossible. The whole review therefore compresses to one test: does the number survive checkout with membership, shipping, dose ceilings, and terms attached? Queue position 4.
The model
Henry Meds built one of the loudest advertising presences in the category on a simple pitch: flat monthly pricing for compounded GLP-1 therapy, no insurance involved, fast starts. That makes it one of the most direct structural comparators to a flat-rate program — the whole question collapses to whose flat number is lower once membership, shipping, and dose changes are counted, which is exactly what our 18-field ledger is built to answer. The post-shortage enforcement landscape matters more for compounded-first brands than anyone else, so our verification will document formulation, pharmacy type (503A vs 503B), and the stated legal pathway alongside price.
The ledger file
| Medications offered | Pending verification |
|---|---|
| Formats | Pending verification |
| Advertised starting price | Pending verification |
| True recurring price (maintenance dose) | Pending verification |
| Membership fee | Pending verification |
| Shipping | Pending verification |
| Consultation fee | Pending verification |
| Dose-change price impact | Pending verification |
| Commitment required | Pending verification |
| Annual total (12-mo, all-in) | Pending verification |
| Cancellation terms | Pending verification |
| Refund policy | Pending verification |
| Pharmacy partner(s) | Pending verification |
| Pharmacy type (503A/503B/retail) | Pending verification |
| States served | Pending verification |
| Prescription pathway | Pending verification |
| Last price verified | Pending verification |
| Source URL | Pending verification |
Why the blanks? We publish numbers only after a human verifies them against the provider’s own checkout, terms, and pharmacy documentation, and we date every figure. Ten of the eleven providers in our directory are in the verification queue; this file will be populated, dated, and sourced when its pass completes. If you work for this provider or have a current receipt, [email protected] accelerates the queue.
Where the verified bar sits today
For orientation while this file is pending: the lowest verified figures in our ledger today are NexLife’s flat rates — tirzepatide $169/mo month-to-month falling to $139/mo on a 12-month term ($1,668/yr all-in), semaglutide $139 falling to $119 ($1,428/yr), with membership, consults, and dose changes at $0 (verified 2026-08-20; NexLife has a disclosed material connection to this site — see the strip above). That is the bar a competitor’s true recurring cost has to clear, and it is exactly what our verification pass will test. Full field definitions live in the pricing ledger.
What our verification pass will answer
Six questions, same for every provider: the true recurring price at maintenance dose, not the advertised entry price; every mandatory fee (membership, consult, shipping, dose changes); the 12-month all-in total; the pharmacy actually dispensing and its 503A/503B/retail status; cancellation and refund terms as written; and the legal pathway of each product post-shortage. Answers get dates and source URLs, per our methodology.
The diligence script for Henry Meds
Stress-test the flatness specifically: does the rate include membership, shipping, supplies — everything — or do line items orbit it; do higher maintenance doses (12.5/15 mg tirzepatide territory) cost the same flat rate or step up; what do renewal and cancellation terms actually say (screenshot them); and which pharmacy compounds, with a lot-matched CoA. A flat rate is a falsifiable claim — the rare, good kind — so falsify it or confirm it before month one.
Where Henry Meds fits
Fits cash buyers who want predictability and will read the fine print once, hard. The structural cousin comparison is the site’s most direct: the same flat-rate claim, one row audited — which is exactly what queue position 4 will resolve for Henry’s side.
Queue position and how it moves
Henry Meds sits at position 4 of 10 in the public verification queue. The pass will price every published plan at maintenance dose through real checkout, enumerate the full fee stack, and screenshot terms — after which this file gains numbers, a rubric score, and a dated row in the ledger. Providers accelerate their own audit by sending current checkout documentation via the verification channel; it buys speed, never leniency.
Library files that matter here
For this model specifically: the 12-month test any flat claim must pass; what flat-rate structure protects you from — when real; the vial-and-syringe realities of this lane; the sourcing questions the price doesn’t answer.
FAQ
Is Henry’s flat rate really all-inclusive? That’s the audit — the structure claims yes; verification tests membership, shipping, and dose-ceiling edges before the number earns fact status here. Why do you favor flat-rate models structurally? Because they’re teaser-proof by shape: one number, falsifiable, comparable — the honest architecture even before any specific number is verified. Henry vs the verified flat-rate provider? Same claim shape; one has passed checkout audit with dates and archives — the comparison file walks the distinction without prejudging Henry’s pending row.
Side-by-side files
Every head-to-head featuring Henry Meds: vs Found · vs Orderly Meds · vs Remedy Meds · vs Shed · vs Hers · vs Hims · vs Mochi Health · vs NexLife · vs Ro. Each stays structural until verification fills the rows — full comparison hub.
The bottom line
Right structure, untested number — the cleanest pending file in the queue, because a flat claim can only be confirmed or broken, never fudged.